登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>Rituximab >RIB-Y36

Anti-Rituximab Antibody (AY36) (recommended for ADA assay)

抗体来源(Source)

Anti-Rituximab Antibodies (recommended for ADA assay) antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Rituximab.

亚型(Isotype)

Mouse IgG1/kappa

特异性(Specificity)

Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Rituximab SDS-PAGE

Anti-Rituximab Antibody (AY36) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Rituximab ELISA

Anti-Rituximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized rituximab at 1 µg/mL, add increasing concentrations of Anti-Rituximab Antibody (AY36) (Cat. No. RIB-Y36, 10% human serum) and then add biotinylated rituximab at 2 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9.7 ng/mL.

Protocol

Rituximab ELISA

Demonstration of the specificity of Anti-Rituximab Antibody (AY36) (Cat. No. RIB-Y36) to the rituximab.

Protocol

 

活性(Bioactivity)-MSD

Rituximab MSD

Anti-Rituximab Antibodies bridging MSD for Anti-Drug Antibody (ADA) assay development. Added the mix solution (biotinylated Rituximab at 5 µg/mL, SULFO-Rituximab at 5 µg/mL and increasing concentrations of Anti-Rituximab Antibody (AY36) (Cat. No. RIB-Y36, 100% human serum). Detection was performed using MSD Assay with a sensitivity of 0.97 ng/mL.

Protocol

 

活性(Bioactivity)-SPR

Rituximab SPR

Anti-Rituximab Antibody (AY36) (mouse IgG1, Cat. No. RIB-Y36) captured on CM5 chip via anti-mouse antibodies surface, can bind human rituximab with an affinity constant of 0.01 nM.

Protocol

 

活性(Bioactivity)-FACS

Rituximab FACS

FACS analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of Anti-Rituximab Antibody (AY36) (Cat. No. RIB-Y36). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.025 μg/ml (Routinely tested).

Protocol

 

背景(Background)

Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定